Ipamorelin is a synthetic pentapeptide derived from GHRP-1, recognized as the first selective growth hormone secretagogue with GHRH-like selectivity for GH release. Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NHâ‚‚ Ipamorelin is derived from GHRP-1 but lacks the central Ala-Trp dipeptide, contributing to its unique selectivity profile. - Primary Target: Ghrelin/GHS receptor (GHS-R) in the hypothalamus and anterior pituitary - Classification: Selective GHRP-receptor agonist - Triggers GH release via the GHRP-like receptor pathway The mechanism involves: 1. Reduction of somatostatin inhibitory signaling 2. Triggering pulsatile GH secretion mimicking natural circadian rhythms 3. GH surge increases circulating IGF-1 levels 4. IGF-1 drives downstream anabolic effects What distinguishes Ipamorelin from other GHRPs: - Does NOT affect FSH, LH, prolactin, or TSH - Does NOT stimulate ACTH or cortisol (even at very high doses) - Highly selective for growth hormone release only This makes Ipam
Ipamorelin: Selective Growth Hormone Secretagogue Research Guide
Understanding Ipamorelin, the first selective growth hormone releasing peptide with minimal effects on other hormones.